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Abstract 
Background: Due to immunosuppressive (IS) therapy, incisional hernias are overrepresented in the 
organ-transplanted (Tx) population with larger defects, a high rate of recurrence and a tendency 
towards more seromas and infectious problems. 
Methods: 31 Tx/IS patients with a control group of 70 non-IS patients with incisional hernia (6/7 
recurrences) were included in a prospective interventional study. Both cohorts were treated with 
laparoscopic ventral hernia repair (LVHR). 
Results: Follow-up time was 37 months with 95% follow-up rate. 100 LVHR were completed as one 
conversion occurred in the Tx/IS group. No late infections or mesh removals occurred. Recurrence 
rates were 9.7% vs. 4.2% (p=0.37) and the overall complication rates were 19% vs. 27% (p=0.80). The 
Tx/IS group had a higher mesh-protrusion rate (29% vs. 13%, p=0.09), but also larger hernias and less 
mesh overlap (p<0.01). Polycystic kidney disease was overrepresented in the Tx cohort (44% of 
kidney-Tx). 
Conclusion: Incisional hernias in Tx/IS patients can be treated by LVHR with the same low 
complication rate and recurrence rate as non-IS patients. By LVHR the serious seroma/infection 
problems encountered in Tx/IS patients treated by conventional, open technique seem almost 
eliminated.  The minimally invasive procedure seems particularly rational in the Tx/Is population, and 
should be the method of choice. (ClinicalTrials.gov number: NCT00455299). 
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Text 
Introduction 
Repair of ventral and incisional hernia by laparoscopy (LVHR) has gained widespread acceptance. 
Especially the smaller and non-loss-of-domain hernias - as well as hernias approximating bony 
structures seem suitably managed by a minimally invasive technique [1]. Even laparoscopic 
component separation and sequentially laparoscopic repair have proven to be feasible options – as 
the hernia surgeons increasingly, in addition to mesh augmentation, find closure of the abdominal 
wall defect important [2-5]. Questions about hernia approximation in laparoscopic hernia repair are 
never the less still unresolved in regard to seroma formation, pain, recurrence and mesh protrusion, 
as are questions concerning mesh fixation [3, 5-7]. The potential benefits of reducing tissue trauma 
compared to open operation would likely be even greater in immunosuppressed patients [8]. By 
avoiding the conventional incision above the mesh, troublesome fluid accumulations causing 
secretion and potentially infection, may be reduced. This may in return reduce the recurrence rate 
[9, 10]. 
Incisional hernias are frequent in the normal population after open abdominal surgery and even 
more frequent in a solid organ transplanted and immunosuppressed (Tx/IS) population [11-13]. 
Recurrence rate after open repair with open technique is high, but can be reduced with the use of 
reinforcing mesh [14, 15]. The low risk of infection by laparoscopy makes the method attractive and 
even more so for the Tx/IS population. Recent studies have proven the feasibility of both open and 
laparoscopic mesh implantation in immunosuppressed patients [10, 16-19]. The literature on 
outcomes of LVHR in the Tx/IS population is limited [1, 9, 10, 16-18, 20]. To our knowledge no 
prospective study with a control cohort in a unified protocol is published. 
The aim of this study is to assess whether LVHR is a safe and effective solution to incisional hernia in 
a Tx/IS cohort in comparison with a non-immunosuppressed (non-IS) cohort by studying how mesh 
overlap, hernia size and randomization to closure/not closure of defect is associated with recurrence, 
protrusion, infection and seroma. 
 
Patients & Methods 
Material 
The study design is a prospective multicentre interventional study with a cohort of Tx/IS patients and 
a control cohort with non-immunosuppressed (non-IS) patients. 101 patients, thirty-one Tx/IS (liver 
or kidney) patients and 70 non-IS patients with incisional hernia including recurrences, situated 
anywhere in the abdominal wall, were enrolled for treatment with LVHR and prospective follow-up 
for a period of three years. The primary incision in all the liver recipients was Mercedes incision and 
oblique or midline incision in the kidney recipients. 
All patients referred with primary (i.e. non-incisional) or incisional hernia in the inclusion period from 
2007 to 2010 were invited – and no patients were excluded due to surgical strategy. Primary hernias 
and recurrences after primary hernias were treated and followed up according to protocol, but as 
these may be a different entity they are not presented in this paper. All patients were Caucasian for 
demographic reasons and all patients have submitted verbal and written informed consent certified 
by the Norwegian Ethical Committee before inclusion. Data handling was approved by the Norwegian 
Data Inspectorate. 
Three surgical centres in Norway participated: two university hospitals and one community teaching 
hospital with emphasis on advanced laparoscopic procedures. One tertiary centre treated all – and 
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only - the Tx/IS patients. LVHR was a novel approach for the Tx-centre but the standard method in 
the non-Tx centres. Firm standards of protocol, close collaboration between centres and only three 
transplant surgeons were involved in order to alleviate this possible learning-curve bias. Of the non-
IS sampled patients 20% were operated at the other university hospital and 80% at the rural 
community teaching-hospital – and there operated or supervised by eight different senior surgeons. 
The study was planned and completed as a randomized controlled multicentre study powered on 
results from a non-published retrospective clinically controlled study on LVHR regarding pain 
duration after different mesh fixation techniques. A shift of focus towards the cohort sub study was 
made as it became clear that the needed number of patients for the randomized study would not be 
reached. 
Surgery 
All patients were operated with laparoscopic technique: Open access or Verres’ needle for creation 
of pneumoperitoneum, three trocars – and in a few patients one or two trocars were added for 
dissection or to accomplish secure mesh fixation. The hernia sac contents were completely reduced 
and the mesh-receiving abdominal wall was stripped of preperitoneal fat. A polyester-based mesh 
with collagen barrier for intraperitoneal use (Parietex Composite, Covidien) was introduced – 
targeted in size for a minimum of 5 cm overlap of the hernia in primary hernia or the whole previous 
incision in incisional hernia – and fixated to the abdominal wall. In order to avoid mesh-exposure to 
intra-abdominal tissues, no mesh was down-sized according to manufacturer’s recommendation. 
Half of the patients were to have approximated the defect before mesh placement. The sample was 
also split in a cross-design for two fixation techniques: four non-absorbable corner stay-sutures and 
one ring of non-absorbable tackers (ProTack, Covidien) and the other half with only tack fixation with 
an outer and an inner ring of tackers, as described by Dr. Morales-Conde. Patients were blindly 
randomized for fixation technique to the four groups: suture-raphe, suture-non-raphe, double 
crown-raphe, double crown-non-raphe. Defect closure was achieved by intracorporeal suture in a 
figure of eight and extrafascial knotting, as described by Dr. Chelala. 
Immunosuppression 
The Kidney-Tx recipients of the Tx/IS-group received quadruple immunosuppression with 
calcineurine inhibitor (CNI) or mammalian target of rapamycin inhibitor (mTOR), basiliximab, 
mycophenolate mofetil (MMF) and corticosteroids. The triple immunosuppressive protocol of the 
liver-Tx recipients consisted of CNI or mTOR, MMF and corticosteroids. At transplantation both liver 
and kidney recipients received a 500 mg methylprednisolone bolus, which was tapered to 20-30 mg 
prednisolone after 8 days, and further weaned to 5 mg prednisolone after 6-12 months. 
At the time of LVHR the recipients received 2.5-15 mg prednisolone, while in two liver recipients 
steroids had been withdrawn.  In addition, 9 of the 31 in the Tx/IS group were on mTOR as part of the 
immunosuppression regime. 
Collection of data  
Patients were invited to non-blinded clinical control at their respective hospitals two months and 
three years after the operation. Patient- or clinician-observed adverse reactions were recorded and 
suspicion of recurrence or protrusion of mesh through hernia defect were examined by sonographic 
specialist with ultrasound including Valsalva manoeuvre and in some patients a CT scan was 
supplementary. Recorded information in addition to the variables presented in table 1 include heart 
disease, type and topography of hernia, previous hernia treatment, access method for laparoscopy, 
number and size of used trocars, pain level (VAS score), pain duration, time to normal activity and 
duration of sick-leave. In the Tx/IS group also previous transplantation and reason for transplantation 
were registered.  
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Primary endpoints were hernia recurrence and mesh protrusion. Mesh protrusion was defined as a 
bulge at the previous hernia defect, but the whole defect is still completely covered and abdominal 
content retained by the implanted mesh. Any perceivable bulging not classified as recurrence after 
clinical and sonographic evaluation was recorded as protrusion in this study.  Protrusion was 
documented as small (≤2.5 cm), medium (2.6-5.0 cm) or large (>5 cm) in prominence above the 
abdominal wall during Valsalva manoeuvre in supine position. Secondary endpoints were 
complications as enterotomy, mesh infection, wound infection, reoperation, seroma formation and 
long-term pain. 
Data calculations & analysis 
A one-dimensional overlap coefficient defined as: the least difference between mesh size and hernia 
size in two directions, divided by the double of the targeted mesh overlap of 5 cm in any direction, 
was calculated. Hernia size in quadratic area (multiplication of hernia length and hernia width, for 
comparison with other studies) as well as a more geometrically sound ellipsoid area calculation (area 
calculation by ellipsoid formula:  π/4* A * B, where A and B are the two diagonals), and the area for 
in-growth derived by subtracting ellipsoid area hernia size from mesh area, was also calculated [21].  
The six studied endpoints were all dichotomous variables. The following study factors were 
categorized into ordinal variables with three categories: hernia area ellipsoid (≤20 cm2, >20 and 100≤ 
cm2, and >100 cm2), ingrowth area (≤200 cm2, >200 and <301 cm2, and ≥ 301 cm2) and overlap 
coefficient (≥1, <1 and ≥0.8, and <0.8). The treatment group was dichotomous (Tx/IS vs. non-IS 
patients) as was defect closure. Four possible confounding variables were considered for adjustment: 
BMI was divided into three categories (≤25 kg/m2, >25 and <30 kg/m2, and ≥30 kg/m2) and age in 
years (<50, ≥50 and <60, and ≥60), while sex and chronic obstructive pulmonary disease (COPD) were 
dichotomous. 
The associations between treatment group and hematoma and re-operation, respectively, were 
analysed bivariate using Fisher’s exact test. The other endpoints were analysed in four multiple 
regression models. The adjusted odds of recurrence and protrusion, respectively, were estimated for 
randomization to defect closure, hernia area ellipsoid, overlap coefficient and treatment group, 
adjusted for BMI, age, chronic obstructive pulmonary disease (COPD) and sex. The same study factors 
were included in the analysis with seroma as the endpoint, but without adjustment for additional 
factors. The odds of infection in the Tx/IS treatment group compared to the non-IS-group was 
adjusted for BMI. 
The significance level was set at five percent in all tests. Odds ratios (OR) with 95% confidence 
intervals (CI) are reported for all study factors included in each regression model, and the p-values 
from the Fisher’s exact tests.  
 
Results 
Two patients in the Tx/IS cohort and three patients in the non-IS cohort with incisional hernia died of 
causes unrelated to hernia surgery before three years follow-up but with updated status at their time 
of death, leaving 96 patients (95%) for the full-time follow-up period of three years. The studied 
cohorts are well matched regarding age, body-mass-index and American Society of Anestesiologists 
physical classification score (ASA), but not in sex (table 1). There was no difference in operating time 
(median 110 min vs. 90 min), or time to normal activity. Of significance was male majority, longer 
admission time, larger hernias, less mesh overlap and a smaller Zuhlke adhesion classification score 
[22] in the Tx/IS group (Table 2). 
As shown in table 3, there were no differences in hematoma, reoperation or infection rate. 
Treatment group and the study-factors were not associated with the adjusted risk of recurrence or 
seroma, but there was a tendency towards less seroma incidence in the Tx/IS cohort (OR=0.23; CI:  
0.02-2.27). No difference was seen in percentage of patients with pain recorded at two months 
(p=0.318), but five patients in the non-IS group have had fixation devices removed: three with 
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removal of suture and two with tacker removal. None of the transplant patients had long term 
fixation device related pain. 
As shown in Table 4 the recurrence rates in the studied cohorts were similar (9.7% vs. 4.2%, p=0.368) 
in univariate comparison. The three patients with recurrences in the Tx/IS group were leaner (mean 
BMI 27 (25-29) vs 32 (28-38)) and younger (mean age 54 vs 62) than the three patients with 
recurrences in the non-IS cohort. Both sexes (two male and one female) were represented in the 
Tx/IS group with recurrence - in the non-IS group there were only female patients [23]. There was no 
correlation between mTOR immunosuppressive therapy and recurrence.The mean hernia area size in 
the Tx/IS cohort was higher (p<0.001), but the mean mesh size used was equal to the control cohort. 
This is reflected by the mean overlap coefficient which in the Tx/IS cohort was 0.7 (i.e. mean overlap 
3.5 cm) and the targeted overlap of 5 cm was reached in only five of 31 patients (16%). 14 patients 
(45%) had a coefficient of 0.8 or higher (i.e. ≥4 cm overlap). In the non-IS cohort the mean overlap 
coefficient was 1.1 (i.e. mean overlap 5.5 cm) and the target was reached in 47 of 70 patients (67%) 
and 66 patients (94%) had an overlap coefficient of 0.8 or more.  
One recurrence occurred in a patient who previously had radiotherapy for treatment of malignant 
lymphatic abdominal disease. She got an unattended iatrogenic colonic perforation and 
consequently had her mesh explanted and thus regained her hernia. She also developed enteric 
fistulae and had a long hospital stay. No other mesh related infection or explantation has been 
observed. Another recurrence was a technical failure as the mesh positioned at primary repair was 
found to be fixated only just tangential to the defect and therefore not augmenting the defect. These 
recurrences were in the non-IS group. 
The adjusted odds ratio for protrusion was 3.69 (CI: 0.70-19.47) in the Tx/IS group compared to the 
non-IS group. Since there were no women with protrusion in the Tx/IS cohort, sex was removed from 
the model. However, the association for the Tx/IS group was also observed when including only men 
in the analysis (OR=3.63; CI: 0.42-31.30).  Male sex was significantly associated with protrusion in a 
bivariate analysis (p<0.001; Fisher’s exact test). In either cohort there were no differences in overlap 
between subgroups with or without protrusion. The hernias in the respective protrusion subgroups 
were larger. However, hernia size was not associated with an increased risk of protrusion but larger 
mesh ingrowth area was (OR=3.46; CI: 1.16-10-35), with additional accentuation in the men-only 
analysis (OR 6.14; CI: 1.19-31.68). The estimated ORs for seroma, recurrence and protrusion were 
independent of how the patients were randomised, as randomisation to defect closure was adjusted 
for in the regression models. However, we found a protective tendency of defect closure in regard of 
protrusion when including only men in the regression analysis (OR=0.16; CI: 0.02-1.18). There were 
no missing values for any of the variables included in the analysis. The detailed results of the 
regression analyses are presented in table 5. One patient became pregnant during the follow-up 
period and completed her pregnancy without adversities [24]. 
 
Discussion 
The Tx/IS population 
The solid organ transplant population is obviously prone to more wound complications and 
recurrences, due to delayed and incomplete wound healing, involving severely affected fibroblast 
proliferation and fibrous repair. Previous studies have shown the hernia defects in the Tx/IS 
population to be distinctly larger [13, 25, 26]. Our data support these findings.  
The impact of these immunosuppressive effects may be demonstrated/examplified by the fact that 
lymphocele/lymph leakage is a major problem after allograft kidney transplantation (KTx) (3-18% 
requiring re-interventions) [27], while in renal auto-transplantation, this problem is almost non-
existent [28]. During recent years, the immunosuppressive treatments have been increased and 
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optimized, resulting in fewer rejection episodes, but probably with more severe adverse effects also 
regarding wound healing. 
Polycystic kidney disease (PKD) is a congenital, systemic disorder affecting fibrous tissue 
development and structure [29]. Interestingly PKD is distinctly overrepresented in our material; 
constituting 7 out of 16 KTx (44%), while the PKD proportion in our KTx population is only 10-12% 
[30]. The debilitating effect of PKD on fibrous healing seems to potentiate the immunosuppressive 
antiproliferative effect. 
The Mercedes incision used in all the liver recipients possibly impact abdominal wall complications. 
The L-shaped incision is now preferred [31]. 
The likely explanation of the distinct preponderance of men (71%) in the Tx/IS group is that more 
men suffer from both kidney and liver failure [26]. We are not able to explain the predominance of 
women (71%) in the non-IS group. Considering a possible learning curve bias we believe it has 
insignificant effect – and any possible effect would serve to emphasize the study conclusions. 
 
Complications/seroma/infection 
One of the most prominent features regarding the Tx/IS patients in this study, is the low rate of 
major postoperative complications (19%). The problem of seroma formation and thereby increased 
infection hazard above the mesh seem almost eliminated with the LVHR approach, quite obviously 
caused by omitting the incision above the mesh. The tendency of lower incidence of seromas in the 
non-IS group may be explained by a reduced inflammatory response caused by the 
immunosuppressive drugs, in particular corticosteroids and mycophenolate mofetil [32]. All detected 
seromas in both cohorts regressed spontaneously before three month without treatment. We 
believe that aspiration of an uninfected seroma is contraindicated for risk of contamination. 
Solely on basis of clinical diagnosis/need for treatment, no unrinary tract infection or venous 
thromboembolic event was recorded. Trocar site infection was also relayed by the patient at two 
month clinical control, as all were either untreated or treated in the primary health sector. 
This study indicates that the low rates of complications in the non-IS population when using LVHR, 
compared to open methods [33, 34], can indeed be conveyed to the Tx/IS patient population. The 
previous reluctance with using synthetic mesh in immunosuppressed patients seems a surpassed 
stage. 
 
Recurrence; causes 
A recurrence rate of about 10% in the Tx/IS population must be considered satisfactory and 
comparable to non-IS patients. Previous studies have also been able to show an equally low 
recurrence rate with LVHR [8-10, 13]. However, methodologically we do consider our three year 
observation period with almost 100% complete follow-up as a strength. The inherently larger hernias 
and immunosuppression (and PKD incidence) in the Tx/IS group would be suspected to cause more 
recurrences [11, 12, 19, 23, 25, 26, 35, 36]. 
Furthermore, the regression analysis (Table 5; on both groups collected) revealed a possible 
association between the factors ‘Hernia size (ellipsoid)’ and COPD with recurrence.  The factor 
‘Overlap coefficient’ only gave rise to an insignificant OR of 1.75. Several authors emphasize the 
importance of sufficient overlap in LVHR, to compensate for mesh shift, positioning and shrinkage, 
but no randomized study has to our knowledge substantiated these claims [37]. 
Recurrences may also be related to awkward hernia localizations, particularly with larger defects in 
the Tx/IS group extending towards the iliac crest or ribs/sternum [38, 39]. The single conversion in 
the Tx/Is group and one of the three recurrences were caused by a potentially insufficient mesh 
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overlap in-between the kidney graft and the iliac crest. In these cases, an open approach should be 
considered. TEKST VEDR. BENNÆRE BROKK. 
 
Protrusion 
The Tx/IS hernias seemed distinctly more prone to mesh protrusion (Table 5: OR 3.69; CI: 0.70-19.47), 
probably due to larger defects, and inferior wound healing, with retarded scar formation and 
diminished mesh shrinking. These relationships have been depicted in Fig. 1.  From obvious physical 
reasons, we consider a larger mesh to be subjected to more peripheral tension and thus protrusion, 
further accentuated with immunosuppression. Even though we did not find any association between 
hernia size and protrusion in the combined cohorts (Table 5: OR 0.98; CI: 0.39-2.51), we think the 
basic data and theoretical considerations are consistent [40]. 
In our study, male sex was associated with protrusion overall and within each cohort (Table 4). The 
great baseline discrepancy regarding sex distribution (71% males in Tx/IS vs 71% females in non-IS) 
does represent a methodological weakness. However, by segregating ‘Men only’ in the regression 
analysis, the same observed elevated risk for protrusion is sustained. Furthermore, there is no 
support from the literature, nor from basic physio-pathological considerations, to favour a sex-
difference regarding protrusion. 
Increased ‘mesh Ingrowth area’ was also associated with development of protrusion (Table 5: OR 
3.46; CI: 1.16-10.35), which may be explained by the fact that a larger hernia, from simple 
mathematical reasons, will require a larger mesh size/area, to secure a 5 cm overlap all around the 
perimeter. 
The increased protrusion rate in the Tx/Is group with significantly larger defects, and the potential 
protective effect of raphe suggested by the men-only regression analysis does support defect 
closure. Thus, we would consider an open, laparoscopic or hybrid procedure in the Tx/IS pouplation 
with larger defects (> 8-12 cm); attempting total fascial closure above the mesh, by layer 
separation/mobilisation [41, 42]. This is also proposed in the recently published European Hernia 
Society guidelines [2]. 
One patient in the Tx/IS population required a successful tightening of the mesh by an open 
procedure by splitting the mesh and overlapping the mesh edges for sufficient tension. Many small 
and medium bulges (<5 cm) are indolent and even unrecognized by the patients. In our experience 
slender patients seem to be less compliant to a bulge and are more perceptive to its presence. This 
may explain the protective association of increasing BMI (OR 0.46; CI: 0.22-0.98).  
 
Type of mesh/fixation devices 
In this study a mesh made of polyester, with a good ingrowth ability [43] and anti-adhesive 
absorbable inside layer was used. Superior ingrowth ability is a key feature in the choice of mesh [44-
46] and probably even more so in the immunosuppressed population [47]. Proposing the use of 
biological meshes in the Tx/IS population seems rational.  In future (disregarding the economic 
aspects), biological ‘decellularised’, ‘scaffold’ meshes may be the chosen material in Tx/IS patients, 
even in uncontaminated circumstances. However, the performance of a disintegrating scaffolding 
mesh in a fibroblast retarded population still needs to be investigated [44, 48]. This study supports 
the feasibility of synthetic mesh implantation in the intra-peritoneal space.  
Though not statistically significant, it is remarkable that no fixation device was found related to long-
term pain in the Tx/IS group, as opposed to the non-IS cohort, with five cases in need of fixation 
material removal. The immunosuppressive medication (involving corticosteroids) may have exerted 
an anti-inflammatory – and thereby analgesic – response [49]. As no undesired effect was observed 
from permanent fixation devices, and impaired inflammation required for ingrowth of mesh is 
expected, a permanent fixation method may be warranted in the Tx/IS population. This could be a 
topic for further investigation.  In response to the observed long-term pain after LVHR with non-
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absorbable mesh-fixation – and to decrease adhesion problems reported with Protack - numerous 
absorbable tacker devices have been marketed, but these were not available at the start of this 
study. Non-absorbable tacker devices have been reported to have less long-term pain, and have – 
despite the lack of substantial clinical studies - replaced the Protack device in many surgical centres. 
The minimally invasive procedure seems particularly justified in the immunosuppressed population, 
and should be the method of choice. These considerations are further accentuated by the 
introduction of more potent anti-proliferative drugs (mTOR/MMF). 
Conclusions 
We found no difference between an immunosuppressed cohort and a non-immunosuppressed 
cohort regarding recurrence or complications after laparoscopic incisional hernia repair. We 
observed a higher rate of protrusion in the Tx/IS group. We conclude that solid organ transplant and 
immunosuppressed patients can be treated with laparoscopic hernia repair with similar results as in 
non-immunosuppressed patients – omitting the troublesome seromas/infections above the mesh - 
and thus qualify as the favoured procedure. 
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Figure legend 
Fig. 1:  Factors/Relationships favouring net-protrusion in immunosuppressed/Tx patients 
 
Table legends 
Table 1 legend: 
Table 1. Laparoscopic incisional hernia repair: Demographic data and patient/disease 
characteristics in a solid organ transplanted and immunosuppressed (Tx/IS) cohort and a non-
immunosuppressed (non-IS) cohort. mTOR = mammalian target of rapamycin inhibitor. 
 
Table 2 legend: 
Table 2. Laparoscopic incisional hernia repair: Perioperative data and events in a solid organ 
transplanted and immunosuppressed (Tx/IS) cohort and a non-immunosuppressed (non-IS) 
cohort. 
Table 2 footnote: 
a Ellipsoid hernia area subtracted from mesh area, b Coefficient of ideal overlap, 1.0 equals 5 cm overlap (ref. 
Methods), c one open adhesiolysis but laparoscopic hernia repair 
 
Table 3 legend: 
Table 3. Laparoscopic incisional hernia repair: Complications in a solid organ transplanted 
and immunosuppressed (Tx/IS) cohort and a non-immunosuppressed (non-IS) cohort. 
 
Table 4 legend: 
Table 4. Laparoscopic incisional hernia repair: Long term outcomes in a solid organ 
transplanted and immunosuppressed (Tx/IS) cohort and a non-immunosuppressed (non-IS) 
cohort. Protrusion size defined by prominence above abdominal wall at Valsalva manoeuvre 
in supine position. PKD = Polycystic Kidney Disease. 
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Table 5 legend: 
Table 5. Laparoscopic incisional hernia repair: Multiple logistic regression on combined 
organ transplant and immunosuppressed (Tx/IS) and non-immunosuppressed cohorts: The 
adjusted odd ratios (with 95% Wald confidence intervals) for recurrence, protrusion, seroma 
and infection for study factors in the multivariate models. Statistically significant values 
(p<0.05) in bold typography. 
 
Table 5 footnote: 
a Adjusted for age and sex. b Adjusted for age. c 4.81 (0.87-26.69) when ingrowth area was included as 
dichotomous variables. d Ellipsoid hernia area subtracted from mesh area. e 16.32 (1.36-196.40) in the middle 
category with the lowest category as reference; 25.33 (1.69-380.20) in the highest category with the lowest 
category as reference. f Coefficient of ideal overlap (ref. Methods). g Chronic obstructive pulmonary disease. 
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Table 1. Laparoscopic incisional hernia repair: Demographic data and patient/disease characteristics 
in a solid organ transplanted and immunosuppressed (Tx/IS) cohort and a non-immunosuppressed 
(non-IS) cohort. mTOR = mammalian target of rapamycin inhibitor. 
 Tx/IS, #=31 Non-IS, #=70 Fisher exact test 
p-value 
Age, years, mean (range) 56 (37-69) 57 (32-81) 0.758 
Body mass index, kg/m2, mean (range) 28 (19-33) 30 (20-50) 0.549 
ASA physical score, 0-E, mean (range) 2.2 (1-3) 1.8 (1-3) 0.001 
Chronic obstructive pulmonary 
disease, # (%) 
6 (19) 9 (13) 0.287 
Female/Male sex, # : # 9 : 22 55 : 15 <0.001 
Recurrent incisional hernias, # (%) 6 (19) 7 (10) 0.165 
Non-recurrent Incisional hernias, # (%) 25 (81) 63 (90) 0.165 
Liver-Tx/Renal-Tx, # : # 15 : 16   
mTor Liver-Tx/Renal-Tx, # : # 4 : 5     
Polycystic kidney disease, # (%) 7 (23)   
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Table 3. Laparoscopic incisional hernia repair: Complications in a solid organ and immunosuppressed 
(Tx/IS) cohort and a non-immunosuppressed (non-IS) cohort. 
 Tx/IS 
 
# (%) 
non-IS 
 
# (%) 
Fischer exact test 
 
p-value 
Intestinal perforation 0 1 (1.4) 0.504 
Omental bleeding 0 1 (1.4) 0.504 
Bladder perforation 1 (3.2) 0 0.674 
Reoperations total 1 (3.2) 2 (2.8) 0.757 
Trocar wound cellulitis 2 (6.5) 5 (7.1) 0.633 
Trocar wound hematoma 0 2 (2.9) 0.126 
Hernia sac seroma 1 (3.2) 9 (12.9) 0.285 
Pneumonia/atelectasis 2 (6.5) 1 (1.4) 0.462 
Urinary tract infection 0 0 1.000 
Thromboembolic event 0 0 1.000 
Mortality 0 0 1.000 
Total 6 (19.4) 19 (27.1) 0.801 
 
Table 4 - LVHR in Tx patients.docx 
Table 4. Laparoscopic incisional hernia repair: Long term outcomes in a solid organ and 
immunosuppressed (Tx/IS) cohort and a non-immunosuppressed (non-IS) cohort. Protrusion size 
defined by prominence above abdominal wall at Valsalva manoeuvre in supine position. PKD = 
Polycystic Kidney Disease. 
 Tx/IS 
 
# (%) 
non-IS 
 
# (%) 
Fischer exact 
test 
p-value 
Odds ratio (95% 
confidence interval) 
binary logistic regression 
Observation time (months) 36 (8-46) 38 (12-73) 0.235  
Recurrence 3 (9.7) 3 (4.2) 0.264  
Protrusion/Eventration 9 (29.0) 9 (12.7) 0.088  
Large (>5 cm) 6 5 0.088  
Medium (2.6-5 cm) 2 2 0.584  
Small (0.1-2.5 cm) 1 2 1.000  
Protrusion, sex distribution 
Female : Male, # : # 
- Combined cohorts 
0 : 9  0.032 Not applicable 
 4 : 5 0.018 0.16 (0.04-0.69) 
4 : 14 <0.001 0.11 (0.03-0.37) 
Protrusion, PKD in Tx cohort 3:7  0.358 2.75 (0.36-21.30) 
Trocar hernia 0 0 1.000  
Hernia reoperations 3 2 0.167  
Pain at 2 months 3 (9.7) 11 (15.3) 0.319  
Removal of fixation material 0 5 (7.1) 0.320  
Local repair of protrusion 1 0 0.674  
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Table 5. Laparoscopic incisional hernia repair: Multiple logistic regression on combined organ 
transplant and immunosuppressed (Tx/IS) and non-immunosuppressed cohorts: The adjusted odds 
ratios (with 95% Wald confidence intervals) for recurrence, protrusion, seroma and infection for 
study factors in the multivariate models. Statistically significant values (p<0.05) in bold typography. 
 Recurrencea Protrusionb Protrusionb 
men only 
Seroma Infection 
Tx/IS cohort 
belonging to 
1.35 
(0.11-17.24) 
3.69 
(0.70-19.47) c 
3.63 
(0.42-31.30) 
0.23 
(0.02-2.27) 
1.11 
(0.19-6.36) 
Hernia size (ellipsoid) 
increasing 
2.53 
(0.45-14.18) 
0.98 
(0.39-2.51) 
0.61 
(0.12-3.04) 
1.30 
(0.46-3.64) 
Not applicable 
(NA) 
Ingrowth aread 
increasing 
0.69 
(0.12-3.96) 
3.46 
(1.16-10.35)e 
6.14 
(1.19-31.68) 
1.34 
(0.46-3.66) 
NA 
Defect closure 
Intended (randomized) 
1.04 
(0.18-6.05) 
0.51 
(0.15-1.71) 
0.16 
(0.02-1.18) 
0.42 
(0.10-1.77) 
NA 
Overlap coefficientf 
decreasing 
1.75 
(0.39-7.90) 
1.33 
(0.50-3.52) 
1.24 
(0.38-4.05) 
NA NA 
COPDg 
present 
2.98 
(0.38-23.62) 
0.82 
(0.18-3.75) 
0.46 
(0.06-3.56) 
NA NA 
Body mass index (BMI) 
increasing 
1.00 
(0.31-3.18) 
0.46 
(0.22-0.98) 
0.58 
(0.18-1.54) 
NA 2.35 
(0.73-7.52) 
a Adjusted for age and sex. b Adjusted for age. c 4.81 (0.87-26.69) when ingrowth area was included as dichotomous 
variables. d Ellipsoid hernia area subtracted from mesh area. e 16.32 (1.36-196.40) in the middle category with the lowest 
category as reference; 25.33 (1.69-380.20) in the highest category with the lowest category as reference. f Coefficient of 
ideal overlap (ref. Methods). g Chronic obstructive pulmonary disease. 
 
 
 
  
